From Sumitomo Dainippon Pharma
to Sumitomo Pharma.

On April 1, 2022, Sumitomo Dainippon Pharma changed its name to Sumitomo Pharma, and will keep on creating the innovative pharmaceuticals and healthcare solutions.

  • Message from the President
  • Movie on Change of Company Name
  • Company Introduction Movie

News

News Releases

  • May 13, 2022 Investors Meeting Presentation for FY2021 (Year ended March 31, 2022) Finances
  • May 13, 2022 Supplementary Financial Data (IFRS) for the Year Ended March 31, 2022 Finances
  • May 13, 2022 Summary of Consolidated Financial Results for the Year Ended March 31, 2022 [IFRS] Finances
  • May 13, 2022 Sumitomo Pharma Announces Changes in Board of Directors and Audit & Supervisory Board Corporate
  • May 10, 2022 Myovant Sciences and Accord Healthcare, Ltd. Enter into Exclusive License Agreement to Commercialize ORGOVYX for Advanced Hormone-Sensitive Prostate Cancer in Europe Licensing

Other Notices

Strengths

  • Research and Development Capabilities
  • Human Resources
  • Global Business Platforms

Sumitomo Pharma seeks to continuously create innovative pharmaceutical products by pursuing R&D activities focused on Psychiatry & Neurology, Oncology, and Regenerative Medicine & Cell Therapy, all the while incorporating cutting-edge technologies.
We also seek to contribute to Global Health through our work in the area of Infectious Disease, and furthermore, through our Frontier Business, we are pursuing R&D and commercialization of new healthcare solutions other than pharmaceuticals for addressing social issues which cannot be solved by pharmaceuticals alone.

At Sumitomo Pharma, we build a strong corporate culture and instill professionalism in our staff through our HR management framework, which brings out the best in talents who are highly capable of achieving results based on their expertise, as well as our company-wide learning and development program. In addition, we are pursuing a variety of initiatives to further strengthen our talents and to enhance diversity and inclusion.

Working Environment which Allow Employees to Work with Their Full Creativity and Motivation

  • Implementing Health and Safety Risk Assessments
  • Promoting Health Management
  • Supporting Mental Wellbeing
  • Preventing of Overwork
  • Operating of Consultation Desks and Hotlines
  • Providing Opportunities for Growth
  • Promoting Work Style Innovation
  • Achieving Work-Life Balance
  • Promoting Diversity and Inclusion
  • Supporting Women’s Active Participation

Sumitomo Pharma
– a company with global business platforms

Sumitomo Pharma has established strong business foundations in Japan, the United States, and China, including local HQ, sales, and R&D functions. We aim to become a Global Specialized Player by becoming a global leader in the three research focus areas of Psychiatry & Neurology, Oncology, and Regenerative Medicine & Cell Therapy, as well as by pursuing our Frontier Business, which is expected to deliver synergy with our pharmaceuticals business, including product development.

  • Research and Development Capabilities
  • Human Resources
  • Global Business Platforms

Sustainability

Sumitomo Pharma defines the practice of its Corporate Mission, "To broadly contribute to society through value creation based on innovative research and development activities for the betterment of healthcare and fuller lives of people worldwide," as CSR-based management. To this end , Sumitomo Pharma is pursuing CSR-based management through a variety of initiatives, including the development of innovative products and healthcare solutions, and contribution to the development of science.


閉じる